Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Kaiser Permanente - Souther California
mi
from
Downey, CA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Kaiser Permanente - Souther California
mi
from
Downey, CA
Click here to add this to my saved trials
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Kaiser Permanente - Southern California
mi
from
Los Angeles, CA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Kaiser Permanente - Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Emory Healthcare
mi
from
Atlanta, GA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Emory Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile
Status: Enrolling
Updated:  1/30/2018
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile
Status: Enrolling
Updated: 1/30/2018
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 Capsules In Patients With Incurable, Stage C or D Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  1/30/2018
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 Capsules In Patients With Incurable, Stage C or D Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 1/30/2018
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated:  2/1/2018
Kaseman Presbyterian Hospital
mi
from
Albuquerque, NM
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated: 2/1/2018
Kaseman Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated:  2/1/2018
Spartanburg Regional Healthcare System
mi
from
Spartanburg, SC
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated: 2/1/2018
Spartanburg Regional Healthcare System
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated:  2/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated: 2/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated:  2/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated: 2/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated:  2/1/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated: 2/1/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vessel Sparing Prostate Radiation Therapy
Vessel Sparing Prostate Radiation Therapy: Dose Limitation to Critical Erectile Structures (Corpus Cavernosum and Internal Pudendal Artery) by MRI Based Treatment Planning
Status: Enrolling
Updated:  2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Vessel Sparing Prostate Radiation Therapy
Vessel Sparing Prostate Radiation Therapy: Dose Limitation to Critical Erectile Structures (Corpus Cavernosum and Internal Pudendal Artery) by MRI Based Treatment Planning
Status: Enrolling
Updated: 2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Enzalutamide + External Beam Rt For Prostate
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated:  2/5/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Enzalutamide + External Beam Rt For Prostate
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated: 2/5/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Enzalutamide + External Beam Rt For Prostate
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated:  2/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Enzalutamide + External Beam Rt For Prostate
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated: 2/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Enzalutamide + External Beam Rt For Prostate
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated:  2/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Enzalutamide + External Beam Rt For Prostate
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated: 2/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Tecemotide (L-BLP25) in Prostate Cancer
A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients
Status: Enrolling
Updated:  2/9/2018
Please Contact US Medical Information
mi
from
Rockland, MA
Tecemotide (L-BLP25) in Prostate Cancer
A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients
Status: Enrolling
Updated: 2/9/2018
Please Contact US Medical Information
mi
from
Rockland, MA
Click here to add this to my saved trials
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated:  2/11/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated: 2/11/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated:  2/11/2018
Weisberg Cancer Treatment Center
mi
from
Farmington Hills, MI
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated: 2/11/2018
Weisberg Cancer Treatment Center
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated:  2/11/2018
NorthShore University Health System
mi
from
Evanston, IL
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated: 2/11/2018
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated:  2/11/2018
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Status: Enrolling
Updated: 2/11/2018
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  2/11/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 2/11/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  2/11/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 2/11/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  2/11/2018
Henry Ford Hospital
mi
from
Detroit, MI
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 2/11/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated:  2/11/2018
Ohio State University Medical Center
mi
from
Columbus, OH
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Status: Enrolling
Updated: 2/11/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Status: Enrolling
Updated:  2/12/2018
Pulmonary and Critical Care Medicine, UCI Medical Center
mi
from
Orange, CA
Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Status: Enrolling
Updated: 2/12/2018
Pulmonary and Critical Care Medicine, UCI Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Status: Enrolling
Updated:  2/12/2018
Urology department, UCI Medical Center
mi
from
Orange, CA
Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer
Status: Enrolling
Updated: 2/12/2018
Urology department, UCI Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
Status: Enrolling
Updated:  2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
Status: Enrolling
Updated: 2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
Phase II Evaluation of MR-Guided Laser Induced Interstitial Thermal Therapy (LITT) for Prostate Cancer
Status: Enrolling
Updated:  2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
Phase II Evaluation of MR-Guided Laser Induced Interstitial Thermal Therapy (LITT) for Prostate Cancer
Status: Enrolling
Updated: 2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy
An Exercise Intervention to Mitigate Side-Effects Related to Androgen Deprivation Therapy Among Prostate Cancer Survivors.
Status: Enrolling
Updated:  2/13/2018
Office of Minority Health and Health Disparities Research
mi
from
Washington,
An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy
An Exercise Intervention to Mitigate Side-Effects Related to Androgen Deprivation Therapy Among Prostate Cancer Survivors.
Status: Enrolling
Updated: 2/13/2018
Office of Minority Health and Health Disparities Research
mi
from
Washington,
Click here to add this to my saved trials
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities
Status: Enrolling
Updated:  2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities
Status: Enrolling
Updated: 2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Birmingham, AL
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Anchorage, AK
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Anchorage, AK
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Aurora, CO
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Louisville, KY
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Baltimore, MD
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Boston, MA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Omaha, NE
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
New York, NY
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Portland, OR
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Burlington, VT
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Jonesboro, AR
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Duarte, CA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Highland, CA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Highland, CA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
La Jolla, CA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Montebello, CA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Montebello, CA
Click here to add this to my saved trials